The impact of Silymarin on improvement of platelet abnormalities in patients with severe preeclampsia
Keywords:
Preeclampsia, Silymarin, Platelet countAbstract
Background: Preeclampsia is a pregnancy-specific disorder that is associated with an increase in blood pressure and proteinuria; in severe cases, it can cause platelet abnormalities. Silymarin is the extract of Silybum marianum, which is recognized as a safe antioxidant drug.
Objective: To determine the impact of Silymarin on the improvement of severe preeclampsia in 60 patients with severe preeclampsia.
Methods: In this double-blind clinical trial study, This study included 60 patients whose pregnancies were terminated because of severe preeclampsia and who were referred to Hajar Hospital in Shahrekord, Iran, from April 2014 to September 2015. The patients were divided randomly into two groups, i.e., a group of 30 patients and a control group of 30 patients. In addition to the current treatments for preeclampsia, The members of the study group were administered 70 mg of Silymarin at three hours and 24 hours after the termination of their pregnancies. The control group received a placebo at the same times. Platelet count tests were compared at the baseline and at 12, 36, and 60 hours post-measurements in the two groups by SPSS software, version 22, by the ANOVA test, and by the independent-samples t-test.
Results: At the baseline, the two groups were not significantly different in terms of various criteria, such as age, BMI, and platelet counts. There were no significant differences between the two groups regarding the number of platelets at 12, 36, and 60 h after their pregnancies were ended (p > 0.01).
Conclusions: The results of this study indicated that, although oxidative factors are involved in the incidence of complications of preeclampsia, e.g., thrombocytopenia, merely using an oxidative agent does not alleviate this effect. This indicated that other factors likely are involved in the pathogenesis of this disease. Additional studies are needed to prove the beneficial effects of this drug in the treatment of preeclampsia.
Clinical trial registration: The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: IRCT201509042388/N1.
Funding: Shahrekord University of Medical Sciences supported this research (project no. 2006).
References
Gary Cunningham F, Jodi S, Kenneth J, Barbara L, Steven L, Jeanne S, et al. Williams Obstetrics. 24th ed.
Newyork: McGraw Hill. 2014; 728-80.
Zhang C, Williams MA, King IB, Dashow EE, Sorensen TK, Frederio IO, et al. Vitamin C and the risk of
preeclampsia resaits from dietary questionnaire and plasma assay. Epidemiology. 2002; 13(4): 409-16. doi:
1097/00001648-200207000-00008. PMID: 12094095.
Gilbert E, Harman J. Manual of high risk pregnancy and delivery. 2th ed. St Louis: Mosby. 2003; 445-62.
Conlin PR, Chow D, Miller ER, Svetkey LP, Lin PH, Harsha DW, et al. The effect of dietary patterns on
blood pressure control in hypertensive patients: Results from the dietary approaches to stop hypertention
(Dash) trial. Am J hypertens. 2000; 13(9): 949-55. doi: 10.1016/S0895-7061(99)00284-8. PMID:
Langmead L, Rampton DS. Review article: Herbal treatment in gastrointestinal and liver disease. Aliment
Pharmacol Ther. 2001; 15(9): 1239-52. doi: 10.1046/j.1365-2036.2001.01053.x. PMID: 11552894.
Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver disease: past, present, future. Phtother
Res. 2010; 24(10): 1423-32. doi: 10.1002/ptr.3207. PMID: 20564545.
Giorgi VS, Peracoli MT, Peracoli JC, Witkin SS, Bannwart-Castro CF. Silibin modulates the NF-kb
pathway and proinflammatory cytokine production by mononuclear cells from preeclamptic women. J
Reprod Immunol. 2012; 95(1-2): 67-72. doi: 10.1016/j.jri.2012.06.004. PMID: 22871551.
Souza CO, Peracoli MT, Weel IC, Bannwart CF, Romao M, Nakaira-Takahagi E, et al. Hepatoprotective
and anti-inflammatory effects of silibin on experimental preeclampsia induced by L-NAME in rats. Life
sci. 2012; 91(5-6): 159-65. doi:10.1016/j.lfs.2012.06.036. PMID: 22781706.
Reid C, Edwards J, Wang M, Manybeads Y, Mike L, Martinez N, et al. Prevention by a silymarin
phospholipid compound of ethanol induced social learning deficits in rats. Planta Med. 1999; 65(5): 421-4.
doi: 10.1055/s-1999-14085. PMID: 10418328.
La Grange L, Wang M, Watkins R, Ortiz D, Sanchez ME, Konst J, et al. Protective effects of the flavonoid
mixture silymarin on fetal brain and liver. J Ethnopharm. 2009; 6(5): 53-61. doi:10.1016/S0378- 8741(98)00144-5. PMID: 10418328.
Kassem LM, Abdelrahim MEA, Naguib HF. Investigating the efficacy and safety of silymarin in
management of hyperbilirubinemia in neonatal jaundice. Med Sci. 2013; 2(2): 575-90. doi:
5455/medscience.2013.02.8057.
Martines G, Pira M, Copponi V, Cagnetta G. silymarin in pregnancy and during hormonal contraceptive
treatment. Arch sci Med (Torino). 1979; 136(3): 443-54. PMID: 549550.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
